Standard BioTools Inc. Restricted Cash, Noncurrent
Standard BioTools Inc. (LAB) had Restricted Cash, Noncurrent of $2.10 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashNoncurrent · last filed 2026-08-05
- 2026-06-30: Restricted Cash, Noncurrent $2.10M.
- 2026-03-31: Restricted Cash, Noncurrent $2.10M.
- 2025-12-31: Restricted Cash, Noncurrent $2.40M.
- 2025-09-30: Restricted Cash, Noncurrent $2.60M.
| Period end | Restricted Cash, Noncurrent |
|---|---|
| 2026-06-30 | $2.10M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $2.10M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $2.40M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $2.60M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $2.60M 10-Q · filed 2025-08-15 |
| 2025-03-31 | $2.60M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $2.10M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.30M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.30M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $1.30M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $800.00K 10-K · filed 2025-03-11 |
| 2022-12-31 | $1.00M 10-K · filed 2024-03-01 |
| 2022-09-30 | $1.00M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.00M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.00M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.00M 10-K · filed 2023-03-14 |
| 2021-09-30 | $1.00M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $1.00M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $1.00M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $1.00M 10-K · filed 2022-03-08 |
| 2020-09-30 | $1.00M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $1.00M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $1.00M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.00M 10-K · filed 2020-02-27 |
| 2019-09-30 | $1.00M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $1.00M 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |